Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ERGOCVE:GPHNASDAQ:SLNNASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERGOEntia Biosciences$0.00$0.00▼$0.00N/A12.3150 shsN/AGPHGraphite OneC$0.92+17.9%C$0.87C$0.55▼C$1.07C$93.15M1.0264,096 shs309,097 shsSLNSilence Therapeutics$5.00-1.2%$3.49$1.97▼$22.47$149.65M1.2300,986 shs139,376 shsSLSSELLAS Life Sciences Group$1.93+2.1%$1.39$0.77▼$2.12$192.57M2.341.51 million shs4.28 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERGOEntia Biosciences0.00%0.00%0.00%0.00%0.00%GPHGraphite One+17.95%+16.46%0.00%-7.07%+5.75%SLNSilence Therapeutics-1.19%-2.72%+48.81%+4.82%-77.18%SLSSELLAS Life Sciences Group+2.12%-0.52%+37.86%+67.83%+37.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/ASLNSilence Therapeutics3.6952 of 5 stars4.44.00.00.03.71.70.6SLSSELLAS Life Sciences Group0.408 of 5 stars0.02.00.00.03.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERGOEntia Biosciences 0.00N/AN/AN/AGPHGraphite One 0.00N/AN/AN/ASLNSilence Therapeutics 2.71Moderate Buy$33.83576.67% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GPH, SLS, ERGO, and SLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.003/7/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/5/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.003/4/2025SLNSilence TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.003/4/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$6.00 ➝ $4.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/ASLNSilence Therapeutics$27.70M5.40N/AN/A$0.71 per share7.04SLSSELLAS Life Sciences Group$1M192.57N/AN/A($0.25) per share-7.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERGOEntia BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AGPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/ASLNSilence Therapeutics-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/ASLSSELLAS Life Sciences Group-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)Latest GPH, SLS, ERGO, and SLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERGOEntia BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERGOEntia BiosciencesN/AN/AN/AGPHGraphite One0.021.090.33SLNSilence TherapeuticsN/A9.319.31SLSSELLAS Life Sciences GroupN/A2.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERGOEntia BiosciencesN/AGPHGraphite One0.07%SLNSilence Therapeutics98.73%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipERGOEntia Biosciences28.30%GPHGraphite One28.81%SLNSilence Therapeutics2.95%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERGOEntia Biosciences6N/AN/ANot OptionableGPHGraphite One20101.25 millionN/ANot OptionableSLNSilence Therapeutics10029.93 millionN/ANot OptionableSLSSELLAS Life Sciences Group1099.78 million69.54 millionNot OptionableGPH, SLS, ERGO, and SLN HeadlinesRecent News About These CompaniesSELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common StockMay 16, 2025 | fxempire.comSellas doses first paediatric subject with AML in Phase II trial of SLS009May 16, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | finanznachrichten.deSELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | globenewswire.comSELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) to Release Earnings on TuesdayMay 8, 2025 | marketbeat.comAnson Funds Management LP Has $1.24 Million Holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)May 5, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025April 28, 2025 | quiverquant.comSELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceApril 28, 2025 | globenewswire.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%April 26, 2025 | aaii.comSELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual MeetingApril 23, 2025 | quiverquant.comSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comSELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLApril 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider ActivityMarch 30, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | finanznachrichten.deSELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trialFebruary 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPH, SLS, ERGO, and SLN Company DescriptionsEntia Biosciences OTCMKTS:ERGOEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.Graphite One CVE:GPHC$0.92 +0.14 (+17.95%) As of 05/27/2025 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Silence Therapeutics NASDAQ:SLN$5.00 -0.06 (-1.19%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$5.02 +0.02 (+0.40%) As of 05/27/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.SELLAS Life Sciences Group NASDAQ:SLS$1.93 +0.04 (+2.12%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.94 +0.01 (+0.73%) As of 05/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.